Neuroscience

Share this article:

Neuroscience

  • Join our comunity:

Meet the Cambridge Scientist on Verge of Curing Multiple Sclerosis

By: , Posted on: June 21, 2017

Dr Su Metcalfe is sitting quietly reading through some documents in the lobby of the Judge Business School when I arrive for our interview. It would be easy to walk right past her and not know you were in the presence of a woman who could be on the verge of curing multiple sclerosis.

MS, an auto-immune condition which affects 2.3 million people around the world, attacks cells in the brain and the spinal cord, causing an array of physical and mental side effects including blindness and muscle weakness. At the moment there’s no cure, but Su and her company, LIFNano, hope to change that.

“Some people get progressive MS, so go straight to the severe form of the disease, but the majority have a relapsing or remitting version,” she says.

“It can start from the age of 30, and there’s no cure, so all you can do is suppress the immune response, but the drugs that do that have side effects, and you can’t repair the brain. The cost of those drugs is very high, and in the UK there are a lot of people who don’t get treated at all.”

Chapter Download: Stem Cell-Based Therapies, Remyelination, and Repair Promotion in the Treatment of Multiple Sclerosis

But now a solution could be in sight thanks to Su, who has married one of the body’s cleverest functions with some cutting-edge technology. The natural side of the equation is provided by a stem cell particle called a LIF.

Su was working at the university’s department of surgery when she made her big breakthrough: “I was looking to see what controls the immune response and stops it auto-attacking us,” she explains.

Dr Su Metcalfe of LIFNano
Dr Su Metcalfe of LIFNano (Photo: David Johnson)

“I discovered a small binary switch, controlled by a LIF, which regulates inside the immune cell itself. LIF is able to control the cell to ensure it doesn’t attack your own body but then releases the attack when needed.

“That LIF, in addition to regulating and protecting us against attack, also plays a major role in keeping the brain and spinal cord healthy. In fact it plays a major role in tissue repair generally, turning on stem cells that are naturally occurring in the body, making it a natural regenerative medicine, but also plays a big part in repairing the brain when it’s been damaged.

“So I thought, this is fantastic. We can treat auto-immune disease, and we’ve got something to treat MS, which attacks both the brain and the spinal cord. So you have a double whammy that can stop and reverse the auto-immunity, and also repair the damage caused in the brain.”

Presumably Su, who has been in Cambridge since she was an undergraduate but retains a soft accent from her native Yorkshire, was dancing a jig of delight around her lab at this point, but she soon hit a snag; the LIF could only survive outside the cell for 20 minutes before being broken down by the body, meaning there was not enough time to deploy it in a therapy. And this is where the technology, in the form of nano-particles, comes in.

“They are made from the same material as soluble stitches, so they’re compatible with the body and they slowly dissolve,” says Su.

“We load the cargo of the LIF into those particles, which become the delivery device that slowly dissolve and deliver the LIF over five days. The nano-particle itself is a protective environment, and the enzymes that break it down can’t access it. You can also decorate the surface of the particles with antibodies, so it becomes a homing device that can target specific parts of the brain, for example. So you get the right dose, in the right place, and at the right time.”

Could LIFNano solve the puzzle of multiple sclerosis?
Could LIFNano solve the puzzle of multiple sclerosis?

The particles themselves were developed at Yale University, which is listed as co-inventor with Su on the IP. But LIFNano has the worldwide licence to deploy them, and Su believes we are on the verge of a step-change in medicine.

She says: “Nano-medicine is a new era, and big pharma has already entered this space to deliver drugs while trying to avoid the side effects. The quantum leap is to actually go into biologics and tap into the natural pathways of the body.

“We’re not using any drugs, we’re simply switching on the body’s own systems of self-tolerance and repair. There aren’t any side effects because all we’re doing is tipping the balance. Auto-immunity happens when that balance has gone awry slightly, and we simply reset that. Once you’ve done that, it becomes self-sustaining and you don’t have to keep giving therapy, because the body has its balance back.”

LIFNano has already attracted two major funding awards, from drug firm Merck and the Government’s Innovate UK agency. Su herself is something of a novice when it comes to business, but has recruited cannily in the form of chairman Florian Kemmerich and ceo Oliver Jarry, both experienced operators in the pharma sector. With the support of the Judge, the company hopes to attract more investment, with the aim of starting clinical trials in 2020.

“The 2020 date is ambitious, but with the funding we’ve got and the funding we’re hoping to raise, it should be possible,” says Su.

“We’ve got everything we need in place to make the nano-particles in a clinically compliant manner, it’s just a case of flicking the switch when we have the money. We’re looking at VCs and big pharma, because they have a strong interest in this area. We’re doing all our pre-clinical work concurrently while bringing in the major funds the company needs to go forward in its own right.”

Immune cells have been a big part of Su’s career, and as we talk, her passion for her subject is obvious. “I wanted to understand something that was so simple on one level but also so complex,” she says.

“The immune cell is the only single cell in the body that is its own unity, so it functions alone. It’s probably one of the most powerful cells in the body because it can kill you, and if you haven’t got it you die because you haven’t got it.”

And MS may just be the start for LIFNano.

“MS is our key driver at the moment, but it’s going to be leading through to other major auto-immune disease areas,” Su adds.

“Psoriasis is high up on our list, and diabetes is another. Downstream there are all the dementias, because a LIF is a major health factor for the brain. So if we can get it into the brain we can start protecting against dementia.”

Now that would be something.

This article was originally published on the Cambridge University website under a Creative Commons Attribution 4.0 International License. Read the original article here.


Translational Neuroimmunology in Multiple Sclerosis

If you found this article interesting, you may be interested in browsing related content on ScienceDirect. We are pleased to offer you a free chapter from the Translational Neuroimmunology in Multiple Sclerosis book called “Stem Cell-Based Therapies, Remyelination, and Repair Promotion in the Treatment of Multiple Sclerosis” below:

Chapter Download: Stem Cell-Based Therapies, Remyelination, and Repair Promotion in the Treatment of Multiple Sclerosis

Visit elsevier.com to access content on autoimmune diseases, immunotherapy and more! Use discount code STC317 at checkout and save up to 30% on your very own copy!

Connect with us on social media and stay up to date on new articles

  • LA Stevens

    Wonderful news. I can see so many uses, should this pass human trials. Can you address Celiac? It’s an auto-immune disease and it all but killed me.

Neuroscience

The scientific study of the nervous system is entering a new golden age. Researchers and clinicians continue to advance the treatment of conditions such as Alzheimer’s syndrome, Parkinson’s disease, epilepsy, and traumatic brain injury. Public initiatives like the federal Brain Research Through Advancing Innovative Neurotechnologies (BRAIN) program in the United States, announced in April 2013, ensure that funding and resources will continue to be applied to this rapidly growing field. Elsevier’s journals, books, eBooks, online references, and tools are respected around the world for everything from physiology and pathology to behavioral genetics and nerve repair. Our publications are a gateway to the latest advancements in neuroscience research and leading-edge data for professionals, students, and academics alike.

Social Media Auto Publish Powered By : XYZScripts.com